The results of the clinical and pharmacoeconomic study of cerebrolysin in the rehabilitative therapy of ischemic stroke presented in the paper revealed the statistically significant regress of neurological disturbances in patients receiving cerebrolysin in daily dosages of 10 and 20 ml as compared to the control group. The rehabilitation of motor functions was more rapid than sensitive ones in patients receiving cerebrolysin comparing to those switched to the basic antihypertensive and antiaggregate therapy. The positive dynamics of speech rehabilitation was observed, the regress of aphatic disturbances being more significant for daily dosage of 20 ml. Rehabilitation rate in the period of treatment with cerebrolysin was higher for daily dosage of 20 ml than that of 10 ml. A prolonged effect of the drug during the long period after its withdrawal was found that resulted in higher rates of rehabilitation to the 11th week in patients receiving cerebrolysin as compared to the control group. Average total cost of direct medical expenses per a patient estimated in the pharmacoeconomic analysis for the groups receiving cerebrolysin and the control group was higher in the former groups, in particular in that with 20 ml dosage of cerebrolysin. A cost-efficacy analysis revealed that the cost of cerebrolysin treatment per effective unit (a cost of one score on the Lindmark scale and the Barthel scale) was less or comparable in patients receiving cerebrolysin comparing to the control group. The study suggests clinical and pharmacoeconomic expediency of cerebrolysin treatment in rehabilitative period of ischemic stroke.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Evaluating the Effectiveness of Neuroprotective Strategies in Enhancing Post-stroke Recovery: A Systematic Review of Meta-Analyses and Clinical Trials.
Cureus
October 2024
Internal Medicine, Nishtar Medical University, Multan, PAK.
This systematic review evaluates the effectiveness of various neuroprotective strategies in enhancing recovery following acute ischemic stroke, focusing on interventions such as normobaric oxygen (NBO), lithium, selective serotonin reuptake inhibitors (SSRIs), and Cerebrolysin. Drawing upon data from six primary studies, including randomized controlled trials (RCTs) and meta-analyses, we assessed these therapies' impact on functional outcomes, motor recovery, and neurological improvement. Normobaric oxygen, across 12 RCTs, demonstrated limited efficacy in improving recovery outcomes or reducing mortality.
View Article and Find Full Text PDF[Cerebrolysin in the preventive therapy of dementia in elderly patients with mild cognitive impairment: a three-year prospective comparative study].
Zh Nevrol Psikhiatr Im S S Korsakova
October 2024
Mental Health Research Center, Moscow, Russia.
Objective: To study the efficacy and safety of long-term (3 years) course Cerebrolysin therapy in an open comparative study as a means potentially capable of slowing or preventing the transition of MCI into dementia, as well as to analyze the possibility of Cerebrolysin preventive effect predicting based on clinical and biological parameters.
Material And Methods: In total, 100 patients with aMCI were included in the study, randomly assigned to 2 groups: patients of group 1 (=50) received annual course therapy with Cerebrolysin for 3 years (20 intravenous infusions of Cerebrolysin 20 ml in 100 ml of saline solution for 4 weeks). Group 2 patients underwent annual clinical examination, but did not receive therapy.
Cerebrolysin Concentrate: Therapeutic Potential for Severe Oral Apraxia After Stroke: A Case Report.
Brain Neurorehabil
July 2024
Department of Rehabilitation Medicine, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon, Korea.
Cerebrolysin concentrate is a medication whose main active ingredient is brain-derived neurotrophic factor. It has been reported to help in the restoration of cognitive function and overall physical function after brain injuries. We present the case of a 72-year-old man with severe oral apraxia due to a left middle cerebral artery ischemic stroke involving the left insular cortex.
View Article and Find Full Text PDFLife-Threatening Anaphylaxis due to Cerebrolysin®.
Case Rep Neurol Med
July 2024
Department for Dermatology and Venereology State Hospital of Wiener Neustadt, Corvinusring 3-5, Wiener Neustadt 2700, Austria.
In this case report, we describe a well-documented, severe anaphylactic reaction after intravenous administration of cerebrolysin, a neurotrophic agent derived from highly purified porcine brain tissue, consisting of peptides and free amino acids. Cerebrolysin has been in use for decades, in various neurological diseases, but especially stroke and traumatic brain injury, with the aim of enhancing cognitive performance. After administration of cerebrolysin to an 85-year-old male patient suffering from subacute stroke, he developed a fulminant anaphylactic reaction.
View Article and Find Full Text PDFPharmacological Treatment of Degenerative Cervical Myelopathy: A Critical Review of Current Evidence.
Neurospine
June 2024
Edinburgh Spinal Surgery Outcomes Study Group, Department of Neurosurgery, Royal Infirmary, Edinburgh, UK.
Article Synopsis
- Degenerative cervical myelopathy (DCM) is a major cause of spinal cord dysfunction in adults, leading to significant health issues and financial costs, with most patients requiring surgery eventually.
- The review examines various pharmacological agents that might help treat mild DCM or improve surgical results, highlighting mixed evidence for effectiveness in both human and animal studies.
- Key findings indicate that while some drugs like Riluzole and Cerebrolysin show potential in animal studies, their benefits in humans are inconclusive, and more robust clinical data is needed to explore new neuroprotective therapies for DCM.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!